Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 1, 2010, Pages 39-46

  Bansal, Geetha P ^a   Malaspina, Angela ^a   Flores, Jorge ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Clinical trial; HIV; Neutralizing antibody; T cell vaccine; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; T CELL VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFICACY; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; INNATE IMMUNITY; MEMORY CELL; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; REVIEW; VACCINATION; VACCINE FAILURE; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS VACCINES; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HIV INFECTIONS; HIV-1; HUMANS; RESEARCH DESIGN;

EID: 76749132657     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 194(12):1661-1671.
2. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 191(5):654-665.
3. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ et al: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 372(9653):1881-1893.
4. Gray G, Allen M, Churchyard G et al: Interim efficacy analysis of HVTN 503/Phambili: A phase IIb test of concept trial of the MRK Ad5 HIV-1 Gag/Pol/Nef vaccine conducted in HIV-1 uninfected adults in South Africa. AIDS Vaccine 2009, Paris, France (2009) 10:Abs SS01-04.
5. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP et al: HIV-1 vaccine-induced immunity in the test-of-concept Step study: A case-cohort analysis. Lancet (2008) 372(9653):1894-1905.
6. Hutnick NA, Carnathan DG, Dubey SA, Cox KS, Kierstead L, Ratcliffe SJ, Robertson MN, Casimiro DR, Ertl HC, Betts MR: Baseline Ad5 serostatus does not predict Ad5 HIV vaccineinduced expansion of adenovirus-specific CD4+ T cells. Nat Med (2009) 15(8):876-878.
7. O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW et al: Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med (2009) 15(8):873-875.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M et al: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 361(23):2209-2220.
9. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, Piatak M Jr et al: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 15(3):293-299.
10. Mascola JR: Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine (2002) 20(15):1922-1925.
11. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR: Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol (2010) 84(3): 1302-1313.
12. Dey B, Svehla K, Xu L, Wycuff D, Zhou T, Voss G, Phogat A, Chakrabarti BK, Li Y, Shaw G, Kwong PD et al: Structurebased stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog (2009) 5(5):e1000445.
13. Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, Mascola JR: Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol (2009) 83(21): 10892-10907.
14. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H: Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods (2008) 329(1-2):112-124.
15. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A et al: Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 458(7238):636-640.
16. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK et al: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 326(5950):285-289.
17. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, Zhang MY, Longo NS, Dimitrov DS: Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 390(3):404-409.
18. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL et al: Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 308(5730): 1906-1908.
19. Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML et al: In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol (2009) 83(8):3617-3625.
20. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B et al: Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 82(23):11651-11668.
21. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M et al: Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2009) 83(2):1045-1059.
22. Gray ES, Madiga MC, Moore PL, Mlisana K, Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L: Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol (2009) 83(21):11265-11274.
23. McHeyzer-Williams LJ, Pelletier N, Mark L, Fazilleau N, McHeyzer-Williams MG: Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol (2009) 21(3):266-273.
24. Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, Matskevitch TD, Wang YH, Dong C: Bcl6 mediates the development of T follicular helper cells. Science (2009) 325(5943):1001-1005.
25. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, Dent AL, Craft J, Crotty S: Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science (2009) 325(5943):1006-1010.
26. Ma CS, Suryani S, Avery DT, Chan A, Nanan R, Santner-Nanan B, Deenick EK, Tangye SG: Early commitment of naive human CD4+ T cells to the T follicular helper (TFH) cell lineage is induced by IL-12. Immunol Cell Biol (2009) 87(8):590-600.
27. Dullaers M, Li D, Xue Y, Ni L, Gayet I, Morita R, Ueno H, Palucka KA, Banchereau J, Oh S: A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity (2009) 30(1):120-129.
28. Fazilleau N, Eisenbraun MD, Malherbe L, Ebright JN, Pogue-Caley RR, McHeyzer-Williams LJ, McHeyzer-Williams MG: Lymphoid reservoirs of antigen-specific memory T helper cells. Nat Immunol (2007) 8(7):753-761. (Pubitemid 46965351)
29. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Reed Clark K: Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med (2009) 15(8):901-906.
30. Luo XM, Maarschalk E, O'Connell RM, Wang P, Yang L, Baltimore D: Engineering human hematopoietic stem/ progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood (2009) 113(7):1422-1431.
31. Letvin NL: Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immun (2006) 6(12):930-939.
32. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G et al: Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2009) 457(7225):87-91. .
33. Barouch DH, Korber B: HIV-1 vaccine development after STEP. Annu Rev Med (2010) 61:153-167.
34. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC: HIV vaccine research: The way forward. Science (2008) 321(5888):530-532.
35. Rhee EG, Barouch DH: Translational mini-review series on vaccines for HIV: Harnessing innate immunity for HIV vaccine development. Clin Exp Immunol (2009) 157(2): 174-180.
36. Ahlers JD, Belyakov IM: Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines. Trends Mol Med (2009) 15(6):263-274.
37. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K et al: Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol (2009) 10(1): 116-125.
38. Sun JC, Lanier LL: Natural killer cells remember: An evolutionary bridge between innate and adaptive immunity? Eur J Immunol (2009) 39(8):2059-2064.
39. Sun JC, Beilke JN, Lanier LL: Adaptive immune features of natural killer cells. Nature (2009) 457(7229):557-561.
40. Tiemessen CT, Shalekoff S, Meddows-Taylor S, Schramm DB, Papathanasopoulos MA, Gray GE, Sherman GG, Coovadia AH, Kuhn L: Cutting edge: Unusual NK cell responses to HIV-1 peptides are associated with protection against maternalinfant transmission of HIV-1. J Immunol (2009) 182(10): 5914-5918.
41. Alter G, Altfeld M: NK cells in HIV-1 infection: Evidence for their role in the control of HIV-1 infection. J Intern Med (2009) 265(1):29-42.
42. Srivastava IK, Kan E, Sun Y, Sharma VA, Cisto J, Burke B, Lian Y, Hilt S, Biron Z, Hartog K, Stamatatos L et al: Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates. Virology (2008) 372(2):273-290.
43. Vagenas P, Williams VG, Piatak M Jr, Bess JW Jr, Lifson JD, Blanchard JL, Gettie A, Robbiani M: Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J Acquir Immune Defic Syndr (2009) 52(4): 433-442.
44. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, Reynes JM, Lopalco L, Bomsel M: HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection: An IgA gene and functional analysis. Mucosal Immunol (2009) 2(5):412-426.
45. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X et al: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA (2008) 105(21):7552-7557.
46. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ et al: The first T cell response to transmitted/ founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 206(6):1253-1272.
47. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L: Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog (2009) 5(9):e1000598.
48. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE et al: Escape from autologous neutralizing antibodies in acute/ early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog (2009) 5(9):e1000594.
49. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M et al: Initial B-cell responses to transmitted human immunodeficiency virus type 1: Virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol (2008) 82(24):12449-12463.
50. Levesque MC, Moody MA, Hwang KK, Marshall DJ, Whitesides JF, Amos JD, Gurley TC, Allgood S, Haynes BB, Vandergrift NA, Plonk S et al: Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 6(7):e1000107.
51. Gasper-Smith N, Crossman DM, Whitesides JF, Mensali N, Ottinger JS, Plonk SG, Moody MA, Ferrari G, Weinhold KJ, Miller SE, Reich CF 3rd et al: Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: Implications for HIV-1 vaccine design. J Virol (2008) 82(15): 7700-7710.
52. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, Roby G, Kottilil S, Arthos J, Proschan MA, Chun TW et al: Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 205(8):1797-1805.
53. Dorner T, Radbruch A: Antibodies and B cell memory in viral immunity. Immunity (2007) 27(3):384-392.
54. Cagigi A, Nilsson A, De Milito A, Chiodi F: B cell immunopathology during HIV-1 infection: Lessons to learn for HIV-1 vaccine design. Vaccine (2008) 26(24):3016-3025.
55. Malaspina A, Moir S, Orsega SM, Vasquez J, Miller NJ, Donoghue ET, Kottilil S, Gezmu M, Follmann D, Vodeiko GM, Levandowski RA et al: Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis (2005) 191(9):1442-1450.
56. Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, Hicks CB, Vandergrift N, Tomaras GD, Haynes BF: HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol (2009) 183(4):2708-2717.
57. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, Rothchild AC, Baker B, Rosenberg R, Cutrell E, Seaman MS, Coffin JM et al: Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis (2009) 200(6):984-990.
58. Walker BD, Burton DR: Toward an AIDS vaccine. Science (2008) 320(5877):760-764.
59. Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, Goodman R, Schneidewind A, Power KA, Toth I, Frahm N, Alter G et al: Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J Virol (2009) 83(4):1845-1855.
60. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL, Brumme ZL, Brumme CJ, Baker B, Rothchild AC et al: HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. J Virol (2009) 83(6):2743-2755.